Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.36 USD
−42.49 M USD
0.00 USD
85.18 M
About Compass Therapeutics, Inc.
Sector
CEO
Thomas J. Schuetz
Headquarters
Boston
Website
Founded
2014
FIGI
BBG00LPXKF25
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CMPX is 1.56 USD — it has increased by 3.31% in the past 24 hours. Watch Compass Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Compass Therapeutics, Inc. stocks are traded under the ticker CMPX.
CMPX stock has risen by 10.64% compared to the previous week, the month change is a −7.69% fall, over the last year Compass Therapeutics, Inc. has showed a −6.59% decrease.
We've gathered analysts' opinions on Compass Therapeutics, Inc. future price: according to them, CMPX price has a max estimate of 10.00 USD and a min estimate of 4.00 USD. Watch CMPX chart and read a more detailed Compass Therapeutics, Inc. stock forecast: see what analysts think of Compass Therapeutics, Inc. and suggest that you do with its stocks.
CMPX reached its all-time high on Apr 16, 2021 with the price of 11.00 USD, and its all-time low was 0.77 USD and was reached on Jul 5, 2024. View more price dynamics on CMPX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CMPX stock is 8.52% volatile and has beta coefficient of 1.54. Track Compass Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Compass Therapeutics, Inc. there?
Yes, you can track Compass Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Compass Therapeutics, Inc. is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
CMPX earnings for the last quarter are −0.08 USD per share, whereas the estimation was −0.11 USD resulting in a 29.11% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about Compass Therapeutics, Inc. earnings.
Compass Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CMPX net income for the last quarter is −10.48 M USD, while the quarter before that showed −13.08 M USD of net income which accounts for 19.85% change. Track more Compass Therapeutics, Inc. financial stats to get the full picture.
No, CMPX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 32.00 employees. See our rating of the largest employees — is Compass Therapeutics, Inc. on this list?
Like other stocks, CMPX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Compass Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Compass Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Compass Therapeutics, Inc. stock shows the sell signal. See more of Compass Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.